MedTrace Logo

Ketamine for Depression: An MRI Study

NCT02544607 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.

Conditions

Interventions

DRUG

Ketamine

Ketamine 0.5mg/kg over 40 minutes IV

OTHER

Magnetic Resonance Imaging (MRI)

MRI technology will be used before and after ketamine for patients with depression

Sponsors & Collaborators

  • Brain & Behavior Research Foundation

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Cristina Cusin, M.D. · MGH

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-12-29
Completion
2017-12-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544607 on ClinicalTrials.gov